Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
By K. Kian Ang, J. Harris, R. Wheeler, R. Weber, D. I. Rosenthal, P. Nguyen-Tan, W. Westra, Christine H. Chung, Richard C. Jordan, Charles Lu and 5 more. New England Journal of Medicine, 2010
5,857 citations recorded by the source corpus.
BACKGROUND Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown. METHODS We performed a retrospective analysis of the association between tumor HPV status and survival among patients with stage III or IV oropharyngeal squamous-cell carcinoma who were enrolled in a randomized trial comparing accelerated-fractionation radiotherapy (with acceleration by means of concomitant boost radiotherapy) with standard-fractionation radiotherapy, each combined with cisplatin therapy, in patients with squamous-cell carcinoma of the head and neck. Proportional-hazards models were used to compare the risk of death among patients with HPV-positive cancer and those with HPV-negative cancer. RESULTS The median follow-up period was 4.8 years. The 3-year rate of overall survival was similar in the group receiving accelerated-fractionation radiotherapy and the group receiving standard-fractionation radiotherapy (70.3% vs. 64.3%; P = 0.18; hazard ratio for death with accelerated-fractionation radiotherapy, 0.90; 95% confidence interval [CI], 0.72 to 1.13), as were the rates of high-grade acute and late toxic events. A total of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tumors; these patients had better 3-year rates of overall survival (82.4%, vs. 57.1% among patients with HPV-negative tumors; P<0.001 by the log-rank test) and, after adjustment for age, race, tumor and nodal stage, tobacco exposure, and treatment assignment, had a 58% reduction in the risk of death (hazard ratio, 0.42; 95% CI, 0.27 to 0.66). The risk of death significantly increased with each additional pack-year of tobacco smoking. Using recursive-partitioning analysis, we classified our patients as having a low, intermediate, or high risk of death on the basis of four factors: HPV status, pack-years of tobacco smoking, tumor stage, and nodal stage. CONCLUSIONS Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer.
Subfields: Otorhinolaryngology, Surgery
View Paper: https://www.semanticscholar.org/paper/e63499863c30834f239fed83867b9f29d7264d20
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Otorhinolaryngology
In Surgery
Citations in the corpus
- PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. (2013, background): “Although these tumors frequently have aggressive histopathological features (2), the presence of HPV DNA is a favorable prognostic factor with regard to recurrence and survival (3-5).”
- Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma (2013, background): “HPV-HNSCCshave favorable clinical outcomeswith survival rates of 82% at 3 years, compared with 57% in non-HPVHNSCCs (6).”
- Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. (2014, methodology): “Cisplatin dose was 100 mg/m(2) on days 1 and 22 of radiotherapy based on projected findings from RTOG 0129, which showed no significant difference between accelerated fractionation plus two cycles of cisplatin and standard fractionation plus three cycles of cisplatin.(17) As in a previous trial, the”
- Comprehensive genomic characterization of head and neck squamous cell carcinomas (2015, methodology): “A low prevalence of an alternative MET transcript with skipped exon 14 was identified in two HPV(2) tumours (Supplementary Fig.”
- Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? (2017, background): “Finally HPV-positive patients do well independently of treatment choice, as long as conforms to the standard of care [2,3,7].”
- Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma (2023, background): “20 months) [49], independently reducing the risk of death by 64% when adjusted for risk factors [50].”
- Oral cavity and oropharyngeal squamous cell carcinoma—an update (2015, methodology): “Nevertheless, in various recent studies, 47% to 71% of patients with HPVpositive OP-SCC have had some history of tobacco use.(78-82) In addition, 61% to 75% of patients with HPVpositive OP-SCC have reported current alcohol use, although only 9% to 18% have been classified as daily or heavy consumers”